Ardena has completed the process of divesting its active pharmaceutical ingredient (API) site in Södertälje, Sweden, to Nanologica AB. Historically, the facility is well established as a drug substance CDMO with a strong track record in small-molecule APIs. Customary closing conditions have been satisfied to complete the transaction.

As a specialist CDMO and bioanalytical CRO, Ardena said it will continue supporting customers with its integrated development approach. Prior to the deal, Ardena and Nanologica shared a long-standing relationship; Ardena now becomes a shareholder in Nanologica.

Sweden Site Continues Under Nanologica

Regarding the Södertälje site, it will operate as a wholly owned subsidiary within the Nanologica Group. It will also revert to its original name, Syntagon AB. Well before this transaction, Ardena acquired Syntagon in May 2018.

In recent years, Ardena said, the facility has benefited from significant investments in chromatographic purification and falling film distillation capabilities. These have helped the site support programs from early development through clinical supply and on to commercial manufacturing.

An ongoing service agreement keeps Ardena as a Nanologica customer, maintaining continuity in precision medicine and other complex therapy development. Also, Ardena CEO Jeremie Trochu will join Nanologica’s Board of Directors.

Trochu said the deal serves to “deliver meaningful patient impact across drug product, nanomedicine, drug conjugates, biomarkers and bioanalysis.”

“It reflects our commitment to ensuring the best long-term future for the Södertälje site and its talented team,” Trochu said. “Nanologica is a partner we know well and is ideally positioned to build on the strong foundation in Södertälje.”

Ardena Making Other Moves

Elsewhere, Ardena is expanding. It has been nearly a year since the company acquired Catalent’s drug product manufacturing facility in Somerset, NJ. That announcement, made in February 2025, included plans for a new bioanalytical lab at the site.

Coverage of that story cracked the list of Contract Pharma’s Top Breaking News Stories of 2025. Click here to see that full list and access the other articles.